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Abstract
Background: Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating
agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy
administration could benefit patients by reducing clinic visits and potentially enhancing on-time chemotherapy
delivery.
Methods: This phase 2, 25-week, open-label study evaluated the noninferiority of darbepoetin alfa administered
weekly vs. as an extended dosing schedule (every 2 or 3 weeks) in patients with CIA. Patients were randomized 1:1 to
an extended dosing schedule (EDS: darbepoetin alfa 300 μg Q2W if chemotherapy was QW, Q2W, or Q4W or
darbepoetin alfa 500 μg Q3W if chemotherapy was Q3W) or weekly (150 μg QW regardless of chemotherapy
schedule). Stratification factors included chemotherapy cycle length, screening hemoglobin (<10 g/dL vs. ≥10 g/dL),
and tumor type (lung/gynecological vs. other nonmyeloid malignancies). The primary endpoint was change in
hemoglobin from baseline to Week 13.
Results: Seven hundred fifty-two patients (374 QW patients; 378 EDS patients) received ≥1 dose of darbepoetin
alfa and were included in the analysis. Demographics and disease state were similar between groups. Seventy-one
percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of ≥11.0 g/dL.
There was a minimal difference in the primary endpoint of mean change in hemoglobin (baseline to Week 13)
between the QW and the EDS groups (-0.04 g/dL; 95% confidence interval: -0.26, 0.17 g/dL). The upper limit of the
95% confidence interval was less than the prespecified limit of <0.75 g/dL, supporting noninferiority of the EDS
dosing schedule. Reported adverse events were similar between groups. A slight increase in transfusions was
reported in the QW group.
Conclusion: Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be
similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events. This study provides
prospective data on how multiple dosing regimens available with darbepoetin alfa can be synchronized with
chemotherapy administered across a range of dosing schedules.
Trial registration: ClinicalTrials.gov Identifier NCT00144131.
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Chemotherapy-induced anemia (CIA) is a common
complication in patients receiving myelosuppressive che-
motherapy, contributing to fatigue and reduced quality
of life [1]. Darbepoetin alfa is a recombinant human ery-
thropoietin approved for treating the symptoms of CIA
by increasing hemoglobin concentrations and thereby
decreasing the incidence of red blood cell (RBC) trans-
fusions [2-5]. The goal of erythropoietin treatment in
the CIA setting is to maintain hemoglobin at a level to
avoid transfusion [6].
In the US, the current darbepoetin alfa prescribing
information includes two dosing regimens for the treat-
ment of CIA [6]. The original approval for CIA in 2002
stipulated a 2.25 μg/kg weekly (QW) dosing regimen. A
subsequent amendment added an extended dosing sche-
dule (EDS) of 500 μg every three weeks (Q3W) to the
prescribing information in 2006. In the EU, a weight-
based dosing of 6.75 μg/kg Q3W is approved for treat-
ment of CIA. Nonetheless, two US medication-use
evaluation studies, utilizing retrospective chart analyses,
have shown that an unindicated initial dose of 200 μg
every two weeks (Q2W) was the most common dosing
choice by physicians at hospital and community oncology
centers in these two studies [7,8]. This alternate extended
dosing regimen most likely arose because many common
chemotherapy regimens progress on a similar Q2W sche-
dule; thus this darbepoetin alfa regimen of 200 μgQ 2 W
may provide greater patient convenience and enhance
adherence to Q2W chemotherapy regimens by reducing
the number of patient visits.
The primary objective of this study was to compare the
efficacy (noninferiority) with respect to change in hemo-
globin of extended dosing darbepoetin alfa (EDS: Q3W
or Q2W) vs. QW darbepoetin alfa for treatment of ane-
mia in patients with nonmyeloid malignancies receiving
multicycle chemotherapy. In addition, secondary objec-
tives evaluated the impact of darbepoetin alfa EDS vs.
QW administration on patient-reported outcomes,
resource utilization, and safety parameters.
Methods
Study population
Eligible patients were at least 18 years of age with active
nonmyeloid malignancies (including lymphocytic leuke-
mias) and anemia defined as screening hemoglobin of less
than 11.0 g/dL. Additionally, eligible patients were
required to be receiving chemotherapy with a planned
additional eight weeks of cytotoxic chemotherapy. Patients
were also required to have an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0 to 2. Patients
with acute myelogenous leukemia, chronic myelogenous
leukemia, or myelodysplastic syndromes were ineligible, as
were patients with angina, hypertension, history of pure
red cell aplasia, or any RBC transfusion within 28 days of
screening. Patients who had received or were planning to
receive myeloablative radiation therapy or who had
received a bone marrow or stem cell transplant six months
prior to screening were also ineligible, as were patients
who had received any erythropoiesis-stimulating agent
(ESA) within 28 days prior to screening.
Study drug
Darbepoetin alfa (Aranesp®, Amgen Inc., Thousand Oaks,
California) was provided as a clear, colorless, sterile, pre-
servative-free protein solution containing 100 μg, 150 μg,
200 μg, 300 μg, or 500 μg of darbepoetin alfa per mL.
Study design
This was a 25-week, randomized, controlled, open-label,
multicenter clinical trial. The study design is summar-
ized in Figure 1. Eligible patients were randomized 1:1
to EDS (darbepoetin alfa 500 μgQ 3 Wi fc h e m o t h e r a p y
was administered Q3W or darbepoetin alfa 300 μg
Q2W if chemotherapy was administered QW, Q2W, or
Q4W) vs. QW (darbepoetin alfa 150 μg QW regardless
of chemotherapy schedule) arms using an interactive
voice-response system. Randomization was stratified by
chemotherapy cycle length (with no more than 35% of
patients receiving QW chemotherapy), hemoglobin at
screening (<10 g/dL vs. ≥10 g/dL), and tumor type
(lung/gynecological vs. all other nonmyeloid malignan-
cies). ESA efficacy may vary with type of chemotherapy,
such as platinum-based therapies, and certain tumor
types (such as lung) are more likely to be treated with
platinum-based chemotherapy. We therefore stratified
by tumor type to minimize the role that chemotherapy
agent could have on outcomes.
In the EDS group, patients received darbepoetin alfa
300 μg Q2W or 500 μgQ 3 W( 3 0 0μg Q2W if che-
motherapy was administered QW, Q2W, or Q4W;
Figure 1 Study design. Stratification was by chemotherapy cycle
length (≤35% QW), hemoglobin at screening (<10 g/dL vs. ≥10 g/dL),
and tumor type (lung/gynecological vs. other nonmyeloid
malignancies).
Schwartzberg et al. BMC Cancer 2010, 10:581
http://www.biomedcentral.com/1471-2407/10/581
Page 2 of 10500 μg Q3W if chemotherapy was administered Q3W).
In the QW group, patients received 150 μg darbepoe-
t i na l f aw e e k l yr e g a r d l e s so f their chemotherapy treat-
ment schedule. Patients who achieved the target
hemoglobin of ≥11.0 g/dL or who had a rapid increase
in hemoglobin (>1.5 g/dL in three weeks for patients
receiving darbepoetin alfa Q3W or >2.0 g/dL in four
weeks for patients in the QW or Q2W group) experi-
enced dose reductions. Patients who exceeded the
hemoglobin threshold of 13.0 g/dL had darbepoetin
alfa withheld until hemoglobin was ≤12.0 g/dL.
T h ep r i m a r ye n d p o i n tf o rt h es t u d yw a st h ec h a n g e
in hemoglobin from baseline to Week 13. Secondary
endpoints included transfusions from baseline to Week
13, improvement in Functional Assessment of Cancer
Therapy-Fatigue (FACT-F) scores, and the frequency of
clinical procedures and impact of clinic visits on activities
of daily life. Tertiary endpoints included hematopoietic
response from baseline to Week 13 and from baseline to
end of treatment, and also the average hemoglobin con-
centration maintained after the target hemoglobin level
was achieved. End of treatment was defined as Week 25,
but could be as early as Week 17 if a patient had at least
8 weeks of chemotherapy and an additional 8 weeks on
study following the last dose of chemotherapy.
This study was conducted at 130 sites in the US and
Canada. The study was conducted in accordance with
the Declaration of Helsinki and the principles of good
clinical practice. All patients gave their written consent
for study participation. Study approval was obtained
from each site’s Institutional Review Board or Institu-
tional Ethics Committee. The study ran from June 2005
to September 2006.
Statistical analysis
In order to establish the noninferiority margin for the
primary endpoint, the results of two large, phase 3, pla-
cebo-controlled trials of 12 weeks duration were exam-
ined: one in patients with lung cancer (n = 314) [5], and
one in patients with lymphoproliferative disease (n =
344) [3]. In a combined analysis of the two trials, the
difference between the darbepoetin alfa (2.25 μg/kg
QW) and placebo groups with respect to the mean (95%
confidence interval [CI]) change in hemoglobin from
baseline to Week 13 was 1.5 g/dL (1.2, 1.8 g/dL). The
noninferiority margin for change in hemoglobin used in
this study, 0.75 g/dL, was based on the concept of pre-
serving 50% of the difference in the mean change in
hemoglobin from baseline to week 13 in the active arm
of the placebo-controlled trials [3,5]. If the upper limit
of the 95% CI for the difference in the mean change in
hemoglobin between the QW regimen of darbepoetin
alfa and the EDS regimen of darbepoetin alfa (QW -
EDS) was not more than 0.75 g/dL, then the conclusion
from this study would be that EDS of darbepoetin alfa is
noninferior to darbepoetin alfa administered QW.
Assuming that the difference in hemoglobin between
the 2 treatment groups is 0.1 g/dL and that the standard
deviation (SD) for the difference in the mean change in
hemoglobin from baseline to Week 13 between the 2
treatment groups was 2.6 g/dL, a total of 750 rando-
mized patients (375 patients per treatment group)
would provide 92% power to demonstrate noninferiority
of EDS to QW dosing schedule based on a noninferior-
ity margin of 0.75 g/dL and a Type I error rate of 5%.
All efficacy analyses were prespecified to be analyzed
on patients who were randomized and received at least
1 dose of study drug. Both last-value-carried-forward
(LVCF) imputation and available-data approaches were
used for the primary endpoint (change in hemoglobin).
An analysis of variance (ANOVA) model was used to
evaluate the change in hemoglobin from baseline to
Week 13. The model contained treatment group, che-
motherapy cycle length (QW vs. Q2W vs. Q3W), screen-
ing hemoglobin (<10 g/dL vs. ≥10 g/dL), and tumor type
(lung/gynecological vs. other nonmyeloid malignancies)
as explanatory variables and change in hemoglobin from
baseline to Week 13 as the response variable. For dichot-
omous efficacy endpoints (receiving a transfusion from
baseline through Week 13, achieving the target hemoglo-
bin level, and achieving a hematopoietic response), the
proportion of patients in each treatment group having
the event was estimated by the Kaplan-Meier (KM)
method; 95% CIs for these parameters were constructed
using Greenwood’s formula for the variance and normal
approximation of the KM proportion. Mean change in
the FACT-F subscore from baseline to Week 13 and
from baseline to end of treatment was analyzed using an
ANOVA model, and the 2-sided 95% CI for differences
between groups was determined. A ≥3-point increase in
FACT-F score was deemed to be clinically significant [9].
The frequency of clinical procedures performed and
frequency of activities impacted by clinic visits from
baseline to Week 13 and from baseline to end of treat-
ment was collected for each treatment group.
Safety
Adverse events were categorized by system organ class
and preferred term according to the MedDRA (v 9.0)
dictionary.
Results
Patient demographics and characteristics
A total of 770 patients were enrolled from 130 sites,
including 386 patients randomized to EDS dosing and
384 patients randomized to QW dosing (Figure 2).
Among those randomized, 378 patients received darbe-
poetin alfa in the EDS arm, and 374 were dosed in the
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study drug (8 for EDS, 10 for QW), the most common
reasons for not receiving study drug were that the
patient either delayed or did not have chemotherapy
(5 patients) or withdrew consent (4 patients), with a
variety of reasons for the remaining 9 patients (such as
screening failure, patient was hospitalized, patient was
on a different chemotherapy schedule, etc.).
Demographic characteristics were mostly balanced
between groups (Table 1). Women outnumbered men in
this study, comprising roughly two-thirds of the sample.
Nearly half of patients in both groups were age 65 years or
older. Breast, lung, and gastrointestinal tumors were the
most common primary tumor types. Overall, about half
the patients had stage IV disease. Among patients with
small cell lung cancer, approximately half were diagnosed
with extensive disease. Mean baseline serum erythropoie-
tin levels were slightly lower in the EDS group than the
QW group (73.4 mU/mL and 86.9 mU/mL, respectively).
Patients in both groups received similar average weekly
doses of darbepoetin alfa. The average weekly dose admi-
nistered to the EDS group (106.8 μg) was comparable to
the average weekly dose administered to the QW group
(98.2 μg). The mean weight-adjusted weekly dose admi-
nistered to the EDS patients (1.5 μg/kg/dose) was similar
to the QW patients’ dose (1.4 μg/kg/dose).
Two hundred twenty-nine patients (61%) in the EDS
arm and 198 patients (53%) in the QW arm completed
the study (Figure 2). Three hundred twenty-five patients
did not complete the study (149 EDS patients [39%] and
176 QW patients [47%]). Common reasons for study
discontinuation included administrative decision, con-
sent withdrawn, death, and adverse event (Figure 2).
Efficacy endpoints
The primary efficacy endpoint was the change in hemo-
globin from baseline to Week 13. Data were adjusted by
screening hemoglobin category, chemotherapy cycle
length, and tumor type. Employing the LVCF approach,
a minimal difference was observed between the QW
group and EDS groups in the least squares mean [95%
CI] change in hemoglobin from baseline to Week 13
(0.90 g/dL [0.74, 1.07] and 0.95 g/dL [0.79, 1.11], respec-
tively) (Table 2). When the available-data approach was
used, the least squares mean (95% CI) was 1.16 g/dL
(0.98, 1.34) for the EDS group and 1.29 g/dL (1.10, 1.47)
for the QW group. The difference between dosing
groups for mean [95% CI] change in hemoglobin level
from baseline to Week 13 was similar, whether deter-
mined using the LVCF (-0.04 g/dL [-0.26, 0.17]) or the
available-data (0.13 g/dL [-0.11, 0.36]) method (Table 2).
Calculated by either method, the upper limit of the 95%
CI was <0.75 g/dL, supporting the noninferiority of EDS
compared with QW dosing. Analysis of individual strata
with large sample sizes, such as screening hemoglobin
<or ≥10 g/dL for each dosing schedule (QW, Q2W, or
Q3W), showed a similar lack of differences between
treatment groups.
The Week 13 KM proportion (95% CI) of patients
achieving the target hemoglobin level of ≥11 g/dL was
Figure 2 Patient disposition (CONSORT diagram). Reasons for
study discontinuation were similar between treatment groups.
Table 1 Patient demographics and clinical characteristics
QW EDS
(n = 374) (n = 378)
Sex, n (%)
Men 148 (40) 126 (33)
Women 226 (60) 252 (67)
Race, n (%)
White 301 (80) 309 (82)
Black or African American 41 (11) 41 (11)
Hispanic or Latino 21 (6) 12 (3)
Asian 5 (1) 7 (2)
Japanese 2 (1) 1 (<1)
Other 4 (1) 8 (2)
Mean (SD) age, years 62.4 (12.5) 62.8 (13.0)
95% CI 61.2, 63.7 61.5, 64.2
Age ≥65 years, n (%) 177 (47) 180 (48)
Age ≥75 years, n (%) 68 (18) 80 (21)
Primary tumor type, n (%)
Breast 100 (27) 112 (30)
Lung 91 (24) 101 (27)
Gastrointestinal 89 (24) 72 (19)
Gynecologic 29 (8) 30 (8)
Leukemia 26 (7) 22 (6)
Genitourinary 17 (5) 20 (5)
Other
a 22 (6) 21 (6)
Patients with stage IV cancer, n (%)
b 183 (52) 179 (50)
Mean (SD) baseline Hb
c (g/dL) 10.1 (0.9) 10.1 (0.8)
aMay include head and neck and hematologic cancer.
bExcludes patients with small cell lung cancer.
cBaseline Hb values within 28 days after RBC transfusion were not excluded or
imputed.
QW = once weekly; EDS = extended dosing schedule; SD = standard
deviation; Hb = hemoglobin.
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QW group (Table 3). When analyzed by baseline strati-
fication factors, anemic patients (with screening hemo-
globin <10 g/dL) with nonmyeloid malignancies
excluding lung/gynecologic malignancies who were
receiving Q3W chemotherapy in the EDS dosing group
(n = 37) achieved the target hemoglobin from baseline
to end of treatment in greater proportion (KM% [95%
CL]) than those in the QW dosing group (n = 36)
(100% [100, 100] vs. 82% [67, 98]). The KM median
[95% CI] time in weeks to target hemoglobin was similar
between the EDS (7.0 [7.0, 9.0]) and the QW (7.0 [6.0,
8.0]) groups (Figure 3). Patients in both dosing groups
maintained similar mean hemoglobin levels after achiev-
ing the target hemoglobin level (Table 3). Eighty-four
percent of patients in the EDS group and 74% of
patients in the QW group were able to maintain hemo-
globin levels between 11 and 13 g/dL. The proportion
of patients who exceeded the hemoglobin threshold
(≥13.0 g/dL) was lower in the EDS group than the QW
Table 2 Change in hemoglobin from baseline to Week 13
QW EDS Difference
(n = 374) (n = 378) (QW - EDS)
LVCF method
n
a 374 375
Least squares mean (95% CI) 0.90 (0.74, 1.07) 0.95 (0.79, 1.11) -0.04 (-0.26, 0.17)
b
Available data method
n
a,c 257 253
Least squares mean (95% CI) 1.29 (1.10, 1.47) 1.16 (0.98, 1.34) 0.13 (-0.11, 0.36)
b
aThree patients in the EDS group were missing screening hemoglobin and were omitted from the ANOVA model.
bThe least squares means and CIs of the treatment difference were computed from an ANOVA model after adjusting for the stratification factors at
randomization (chemotherapy cycle length, screening hemoglobin, and tumor type).
cPatients missing hemoglobin values at Week 13 were omitted from the analysis.
QW = once weekly; EDS = extended dosing schedule; LVCF = last value carried forward; CI = confidence interval; ANOVA = analysis of variance.
Table 3 Secondary efficacy endpoints
QW EDS
(n = 374) (n = 378)
Patients who achieved Hb ≥11 g/dL from baseline to Week 13
Patients included in the analysis
a 323 334
KM% (95% CI) 76 (70, 81) 71 (66, 77)
Average Hb after achieving Hb ≥11 g/dL
Patients included in the analysis
b 301 304
Mean (95% CI) 11.6 (11.5, 11.7) 11.8 (11.7, 11.9)
Category - %
<11 g/dL 22 13
11 to 13 g/dL 74 84
>13 g/dL 44
Patients who had a hematopoietic response from baseline to Week 13
Patients included in the analysis 374 378
KM% (95% CI) 59 (53, 64) 53 (48,59)
Patients who had a hematopoietic response from baseline to end of treatment
Patients included in the analysis 374 378
KM% (95% CI) 86 (82, 91) 84 (79, 88)
Patients who had an RBC transfusion from baseline to Week 13
Patients included in the analysis 374 378
KM% (95% CI) 25 (20, 29) 20 (16, 24)
Patients who had an RBC transfusion from baseline to end of treatment
Patients included in the analysis 374 378
KM% (95% CI) 29 (24, 34) 26 (21, 30)
aPatients who had Hb values ≤11 g/dL at baseline were included in the analysis.
bPatients who achieved Hb ≥11 g/dL or who had Hb values ≥11 g/dL at baseline were included in the analysis.
QW = once weekly; EDS = extended dosing schedule; Hb = Hemoglobin; CI = confidence interval; KM = Kaplan-Meier.
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13 and also from baseline to the end of treatment (31%
vs. 37%). Fewer patients experienced a rapid rise in
hemoglobin (>2.0 g/dL in 4 weeks for patients receiving
darbepoetin alfa QW or Q2W or >1.5 g/dL in 3 weeks
for patients receiving darbepoetin alfa Q3W) in the EDS
group than in the QW group from baseline to Week 13
(27% vs. 46%, respectively) and from baseline to end of
treatment (36% vs. 56%).
Hematopoietic response, defined as an increase in
hemoglobin ≥2 g/dL from baseline or a hemoglobin value
of ≥12.0 g/dL in the absence of any transfusions within the
previous 28 days, was assessed from baseline to Week 13.
The hematopoietic response was slightly lower in the EDS
g r o u pt h a ni nt h eQ Wg r o u p( 5 3 %v s .5 9 % )( T a b l e3 ) .
A smaller proportion of EDS patients had a hematopoi-
etic response in the groups with screening hemoglobin
<10 g/dL, nonmyeloid malignancies excluding lung/gyne-
cologic malignancies, and QW or Q3W chemotherapy
strata than did QW patients (data not shown).
Patients who received QW dosing appeared to have a
slightly greater number of transfusions compared with
the EDS group. This was true for transfusions received
from baseline to study Week 13 or from baseline to the
end of treatment (Table 3). The mean (SD) number of
RBC units transfused from baseline to Week 13 was 0.5
(1.3) units in the EDS group compared with 0.7 (1.4)
units in the QW group, and 0.7 (1.6) units and 0.8 (1.7)
units, respectively, from baseline to the end of treatment.
Patient-reported Outcomes
The change in FACT-F score was measured from base-
line to Week 13 as a secondary endpoint using the avail-
able-data approach (Table 4). A greater mean [95% CI]
change in FACT-F score was seen in the EDS group (2.5
[1.2, 3.7]) compared with the QW group (1.8 [0.5, 3.1]),
which resulted in a mean (95% CI) difference between
groups (QW - EDS) of -0.7 (-2.3, 0.9). When data were
analyzed by the stratification factors used at randomiza-
tion, an interaction between treatment and hemoglobin
category at screening was observed, indicating that the
difference in FACT-F scores between dosing groups was
not consistent across screening-hemoglobin categories.
Similar percentages of patients in both treatment groups
experienced a clinically significant ≥3-point increase in
FACT-F score from baseline through Week 13 or end of
treatment (Table 4).
Resource Utilization
The mean [SD] number of most clinic procedures from
baseline to Week 13 was lower among patients in the
EDS group compared with the QW group, including lab
tests/blood draws (9.9 [4.2] vs. 12.5 [4.8]) and injections
(4.9 [3.6] vs. 8.9 [5.6]). In patients receiving darbepoetin
alfa Q2W in the EDS group, the mean (SD) number of
lab tests/blood draws was 10.5 (4.2) and the mean (SD)
number of injections was 5.5 (3.8). In patients receiving
darbepoetin alfa Q3W in the EDS group, the mean (SD)
number of lab tests/blood draws was 9.2 (4.1) and the
mean (SD) number of injections was 4.1 (3.0). Similarly,
over the first 13 weeks of treatment, the mean (SD)
number of activities impacted by clinic visits was
reported to be lower by patients receiving EDS dosing
compared with the QW group with respect to both paid
employment (4.1 [7.8] in the QW group; 2.9 [6.0] in the
EDS group; 3.0 [6.0] in patients receiving darbepoetin
alfa Q2W in the EDS group; and 2.7 [6.1] in patients
receiving darbepoetin alfa Q3W in the EDS group) and
house/yard work (6.7 [8.9] in the QW group; 4.9 [7.4] in
the EDS group; 4.6 [7.6] in patients receiving darbepoe-
tin alfa Q2W in the EDS group; and 5.4 [7.1] in patients
receiving darbepoetin alfa Q3W in the EDS group).
Safety
O v e rt h ec o u r s eo ft h i ss t u d y ,m o s tp a t i e n t s( 9 5 % )
experienced at least one adverse event (Table 5). The
type and incidence of adverse events were similar
between the EDS and QW dosing groups, with fatigue
(22% in both groups) being the most common. The only
adverse event with a ≥5% difference between groups was
anemia, with an incidence of 6% in the EDS group and
11% in the QW group.
The incidence of serious adverse events was slightly
lower in the EDS group (133 patients, 35%) than in the
QW group (154 patients, 41%). Serious adverse events
occurring in ≥5% of patients in either the EDS or QW
treatment group were disease progression (5% each),
dehydration (6%, 5%), and pneumonia (2%, 5%). Treat-
ment-related adverse events were reported in 14 EDS
patients (4%) and 18 QW patients (5%). In 3 EDS patients
Figure 3 Kaplan-Meier curve of the time to target hemoglobin
from baseline to Week 13. The time to reach the target
hemoglobin of ≥11.0 g/dL was similar for both treatment groups.
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adverse events were considered serious (Table 5). One
patient in the QW dosing group experienced a moderate
myocardial infarction at Week 22, which resolved after 7
days. A second QW patient experienced severe neutrope-
nia and severe pyrexia during the first study week that
resolved after 4 days. An EDS patient experienced a life-
threatening pulmonary embolism at Week 18 that
resolved after 15 days. A second EDS patient experienced
severe arthralgia during the first study week that resolved
after 6 days. A third EDS patient experienced a severe
pulmonary embolism at Week 2 that resolved after 4
days. All 5 patients continued on study. Life-threatening
adverse events were reported for 16 EDS patients (4%)
and 22 QW patients (6%). Overall, 78 patients (n = 39
[10%] in each group) died on study. The only adverse
event leading to death in >1% of patients (n = 11 [3%] in
each group) was disease progression, which was also the
most common adverse event leading to study disconti-
nuation (4% in each group). During the course of this
study, 46 patients (12%) in the EDS group, and 58
patients (16%) in the QW group discontinued from the
study because of adverse events.
The incidence of thromboembolic events was similar
between dosing groups, occurring in 6% of patients in
each group (Table 5). This rate was consistent with that
described in the prescribing information for darbepoetin
alfa. In both EDS and QW groups, deep vein thrombosis
(2% EDS, 4% QW), pulmonary embolism (2% EDS, 1%
QW), and phlebitis (1% in each group) were the most
common thromboembolic events. Among patients who
experienced thromboembolic events, 11 patients (52%)
in the EDS group and 15 patients (65%) in the QW
group had Stage IV disease.
A separate analysis of adverse events due to safety
concerns of historic interest was undertaken. These
included: neoplasms benign, malignant, and unspecified
(including cysts and polyps); embolism/thrombosis;
arrhythmias; congestive heart failure; hypertension; cere-
brovascular accident; myocardial infarction/coronary
artery disorders; immune system disorder; and seizure.
One hundred EDS patients (26%) and 106 QW patients
(28%) reported such events. Neoplasms benign, malig-
nant, and unspecified was the most frequent category,
occurring in 54 EDS patients (14%) and 59 QW patients
(16%) (Table 5).
Neutralizing antibodies to darbepoetin alfa were not
detected in any patient (n = 746 patients with samples
available for testing). Binding, nonneutralizing antibodies
to darbepoetin alfa were observed in 56 (7.5%) of the
746 patients who had test results. This included pre-
existing antibodies in 49 (6.6%) patients who were anti-
body-positive at screening and 7 (0.9%) patients who
were antibody-positive only at post-treatment. These 7
patients all developed a low-level antibody response
(< 0.5 μg/mL).
Discussion
In this study of patients diagnosed with nonmyeloid
malignancies receiving multicycle chemotherapy and
treated with darbepoetin alfa for CIA, the primary
objective was to establish the noninferiority of an EDS
regimen compared with a QW dosing regimen. The
EDS and QW dosing groups in the study achieved a
similar mean change in hemoglobin from baseline to
Week 13 (1.16 g/dL and 1.29 g/dL, respectively, using
the available data approach, or 0.95 and 0.90 g/dL,
respectively, using the LVCF approach). We observed
Table 4 Change in FACT-F score
QW EDS Difference
(n = 374) (n = 378) (QW - EDS)
Baseline FACT-F score
Patients included in the analysis
a 330 337
Mean (SD) 29.7 (12.4) 29.9 (12.4)
Change in FACT-F score from baseline to Week 13
Patients included in the analysis
b 256 268
Least squares mean (95% CI)
c 1.8 (0.5, 3.1) 2.5 (1.2, 3.7) -0.7 (-2.3, 0.9)
≥3-point increase in FACT-F score from baseline
Patients included in the analysis
a 330 337
Through Week 13, n (%) 111 (34) 132 (39)
Through the end of treatment, n (%) 155 (47) 173 (51)
aPatients missing a valid baseline and post-baseline FACT-F score were omitted from the analysis.
bPatients missing a valid baseline and Week 13 FACT-F score were omitted from the analysis.
cThe least squares means and CIs were computed from an ANOVA model after adjusting for the stratification factors at randomization (chemotherapy cycle
length, screening hemoglobin, and tumor type), and baseline FACT-F score.
FACT-F = Functional Assessment of Cancer Therapy-Fatigue; QW = once weekly; EDS = extended dosing schedule; SD = standard deviation; CI = confidence
interval; ANOVA = analysis of variance.
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between groups was less than 0.75 g/dL, thus supporting
the noninferiority of EDS dosing compared with QW
dosing regimens. In addition, the number of patients
who underwent transfusions was similar in both groups
at 20% EDS and 25% QW from baseline to Week 13,
and 26% EDS and 29% QW from baseline to end of
treatment. Both EDS and QW dosing schedules were
well tolerated, with similar safety profiles. These results
suggest that darbepoetin alfa can be administered QW,
Q2W (an unindicated schedule), or Q3W for the treat-
ment of CIA in patients with nonmyeloid malignancies,
allowing synchronization with a variety of chemotherapy
regimens.
These findings are aligned with previous studies that
have compared EDS regimens of darbepoetin alfa to
QW regimens and have shown equivalent efficacy. One
study of darbepoetin alfa 200 μg Q2W vs. Epoetin alfa
QW in 1209 patients with CIA targeted hemoglobin
levels of 11 to 13 g/dL and demonstrated noninferiority
of the Q2W regimen [10]. In a study of patients receiv-
ing darbepoetin alfa 500 μg Q3W vs. 2.25 μg/kg QW by
Canon et al [11], a comparable number in each group
achieved a target hemoglobin range of 11 to 13 g/dL as
did patients in the current study. Additionally, these
authors also reported that the Q3W arm was noninfer-
ior to the QW arm in regards to incidence of RBC
transfusion from Week 5 to end of study (23% in the
Q3W group vs. 30% in the QW group), which is consis-
tent with our observations.
We also evaluated the impact of EDS and QW adminis-
trations of darbepoetin alfa on patient-reported outcomes
Table 5 Adverse events reported on study
Type of Adverse Event QW
(n = 374)
n (%)
EDS
(n = 378)
n (%)
Patients who had any adverse events 357 (95) 360 (95)
Patients who had adverse events of historical interest 106 (28) 100 (26)
Neoplasms benign, malignant and unspecified 59 (16) 54 (14)
Embolism/thrombosis 23 (6) 21 (6)
Deep vein thrombosis 14 (4) 9 (2)
Pulmonary embolism 2 (1) 9 (2)
Phlebitis 2 (1) 2 (1)
Jugular vein thrombosis 0 (0) 1 (<1)
Subclavian vein thrombosis 0 (0) 1 (<1)
Superior vena caval occlusion 0 (0) 1 (<1)
Thrombophlebitis superficial 2 (1) 1 (<1)
Thrombosis 2 (1) 1 (<1)
Atrial thrombosis 1 (<1) 0 (0)
Phlebitis superficial 1 (<1) 0 (0)
Arrhythmias 19 (5) 12 (3)
Congestive heart failure 12 (3) 10 (3)
Hypertension 10 (3) 9 (2)
Cerebrovascular accident 2 (1) 7 (2)
Myocardial infarction/coronary artery disorders 4 (1) 5 (1)
Immune system disorders 0 (0) 3 (1)
Seizure 3 (1) 2 (1)
Patients who had treatment-related adverse events 18 (5) 14 (4)
Patients who had serious adverse events 154 (41) 133 (35)
Patients who had serious treatment-related adverse events 2 (1) 3 (1)
Pulmonary embolism 0 (0) 2 (1)
Arthralgia 0 (0) 1 (<1)
Neutropenia 1 (<1) 0 (0)
Myocardial infarction 1 (<1) 0 (0)
Pyrexia 1 (<1) 0 (0)
Patients who had life-threatening adverse events 22 (6) 16 (4)
Patients who discontinued from the study because of adverse events 58 (16) 46 (12)
Patients who died 39 (10) 39 (10)
QW = once weekly; EDS = extended dosing schedule.
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were observed between dosing groups in the mean
change in FACT-F scores from baseline to Week 13,
overall improvements in FACT-F scores compared favor-
ably with other studies of EDS vs. QW dosing, with
approximately 35% of patients achieving a 3-point
improvement by Week 13 and about 50% by end of treat-
ment [10-13]. In terms of resource utilization, the num-
ber of many types of clinic procedures and the number of
activities impacted by clinic visits (such as paid employ-
ment and house/yard work) were lower in the EDS group
compared with the QW group; this observation was also
seen when the separate Q2W and Q3W dosing groups in
the EDS arm were compared with the QW group.
Thromboembolic events represent a recognized risk
that is reflected in product labeling for ESAs as a class.
Rates of embolism/thrombosis reported in this study
were similar to those previously reported [6]. Other dar-
bepoetin alfa investigations examining EDS dosing have
reported thromboembolic rates similar to that observed
in QW dosing, supporting the safety of this dosing regi-
men in CIA [10-12]. Although the safety profile was
similar for both dosing groups, this study was unable to
provide comparative safety data for darbepoetin alfa
because of the lack of an untreated control group.
A large proportion of patients did not complete the
study (39% EDS, 47% QW). Administrative/investigator
decisions were responsible for the most study disconti-
nuations; the most frequent reasons given were cessa-
tion of chemotherapy and lack of response to the study
dose of darbepoetin alfa. In spite of the high attrition
rate, the reasons for study discontinuation were
balanced between groups and the resulting analysis set
was representative of the study population.
While the use of ESAs for the effective treatment of
CIA is well supported by the evidence base, data recently
published from eight individual studies in patients receiv-
ing ESAs for cancer-related anemia have raised concerns
regarding increased mortality [3,14-20]. These studies
explored experimental, unindicated ESA use either at
high hemoglobin targets or in non-CIA indications. Pro-
duct labeling for ESAs has been revised to state that
ESAs shortened overall survival and/or time to tumor
progression in clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervi-
cal cancers [6]. Legitimate concerns remain that these
risks have not been adequately excluded in the labeled
setting and have prompted initiation of additional large,
well-controlled studies specifically exploring the effect of
ESAs on mortality and tumor progression when adminis-
tered in accordance with approved labeling. The current
study did not demonstrate any apparent difference in
survival or progression between the different darbepoetin
alfa regimens, but was not powered to address questions
of survival or tumor progression and had no untreated
concurrent control group for comparison.
This study provides evidence for the utility and effi-
cacy of darbepoetin alfa extended dosing, and for the
ability to synchronize dosing with chemotherapy admin-
istration. This extended dosing offers potential advan-
tages for patient convenience and clinic efficiency.
Conclusion
Patients receive chemotherapy on a variety of schedules
(QW, Q2W, Q3W or Q4W). The ability to synchronize
therapy for CIA with chemotherapy could allow for
greater patient convenience and may enhance compli-
ance - provided efficacy is comparable. In this study, we
demonstrated the noninferiority of darbepoetin alfa
given on an EDS vs. QW dosing regimen, with similar
mean changes in hemoglobin, proportions of patients
receiving transfusions, and safety profiles. Patients
receiving darbepoetin alfa on the EDS schedule had
fewer activities of daily living impacted by clinic visits.
Thus, EDS darbepoetin alfa offers comparable efficacy
with QW dosing but with potential enhanced benefits
for patient quality of life.
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